Axovant shares plunge after key drug program scrapped
(Reuters) - Axovant Sciences Ltd's shares fell nearly 50 percent on Monday after the company scrapped its intepirdine program following the failure of its lead experimental treatment in a mid-stage study on patients suffering from a type of dementia.
from Reuters: Health News http://reut.rs/2mecztm
http://bit.ly/2zwRqiM